Zenas BioPharma, Inc. (ZBIO)
| Market Cap | 397.93M |
| Revenue (ttm) | 5.00M |
| Net Income (ttm) | -156.99M |
| Shares Out | 41.80M |
| EPS (ttm) | -11.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 169,394 |
| Open | 11.00 |
| Previous Close | 11.24 |
| Day's Range | 9.32 - 11.00 |
| 52-Week Range | 5.83 - 26.25 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 32.29 (+239.18%) |
| Earnings Date | May 20, 2025 |
About ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb for the treatment of several I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFα monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associa... [Read more]
Financial Performance
In 2024, Zenas BioPharma's revenue was $5.00 million, a decrease of -90.00% compared to the previous year's $50.00 million. Losses were -$156.99 million, 322.9% more than in 2023.
Financial numbers in USD Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ZBIO stock is "Strong Buy." The 12-month stock price forecast is $32.29, which is an increase of 239.18% from the latest price.
News
Cohen Milstein Reminds Zenas BioPharma (ZBIO) Investors of Opportunity to Lead Securities Fraud Suit
Cohen Milstein reminds Zenas BioPharma (ZBIO) investors of an opportunity to lead a securities fraud class action. Lead plaintiff deadline - June 16, 2025.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
NEW YORK CITY, NY / ACCESS Newswire / May 3, 2025 / Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Zenas To Contact Him Directly To ...
Cohen Milstein Seeks Investors to Lead Suit to Hold Zenas BioPharma (ZBIO) Accountable for IPO-Related Fraud
WASHINGTON, D.C., May 01, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (NASDAQ: ZBIO) entered the public markets in September 2024 with a $17 per share debut and bold projections.
Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses
WASHINGTON, April 22, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating potential securities fraud claims on behalf of investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) who ...
Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses
WASHINGTON, April 21, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating potential claims on behalf of investors who purchased securities of Zenas BioPharma, Inc. (NASDAQ: ZB...
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Zenas BioPharma, Inc. (ZBIO)
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachus...
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the...
Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst
Dual inhibition of CD19 and FcyRIIb leads to broader B-cell depletion coverage compared to that of other CD19 and CD20 inhibitors. Zenas BioPharma, Inc.'s topline 12-week results, from the phase 2 Moo...
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and strategy Dr. Laken brings over 25 years of leadership experience in research, dev...
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
On Thursday, Wedbush initiated coverage on Zenas BioPharma, Inc. ZBIO, a clinical-stage global biopharmaceutical company focused on developing therapies for autoimmune disease.
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies–
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in...
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the ...
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy-
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
-INDIGO is the largest clinical trial conducted in patients living with IgG4-RD- -Topline INDIGO results expected by the end of 2025- WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma,...
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
WALTHAM, Mass, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the d...
Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and ...
U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market
Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand...
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and ...
U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows
Two small IPOs and two SPACs debuted this past week - Pheton Holdings, Powell Max, Vine Hill Capital, and Andretti Acquisition II, respectively. Eight IPOs submitted initial filings this past week, in...
Zenas BioPharma Seeks IPO For Inflammatory Treatment Trials
Zenas BioPharma has filed to raise $100 million in an IPO to advance its Phase 3 and Phase 2 trials for obexelimab, although the final figure may differ. The company is developing antibody-based treat...
U.S. IPO Weekly Recap: WeRide Delays Its IPO As Pipeline Gets A Boost
Two small IPOs debuted this past week, while six IPOs submitted initial filings. Six IPOs submitted initial filings this week, including four names which filed to raise $100 million or more. There are...